ArticleANZ journal of surgery2026
Temporal Trends in Intracavernosal Injection Therapy and Penile Prosthesis Implantation in the Era of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Australia.
Article in ANZ journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhosphodiesterase-5 inhibitors (PDE5-Is) transformed erectile dysfunction (ED) management as first-line therapy; nonetheless, many patients require second- and third-line options due to inadequate response, side effects, or contraindications. This article evaluates temporal trends in intracavernosal injection (ICI) therapy and penile prosthesis implantation (PPI) in Australia since PDE5-Is introduction.
methodsMBS item numbers 37415 (ICI), and 37429/37426 (PPI) from 1998 to 2024 were analysed. Data were stratified by age and state, standardised to Australian male population estimates, and reported per 100 000 men. Compound annual growth rates (CAGR) were calculated with break points at major events (release of PDE5-Is, generics, COVID-19). RPBS data were extracted for eligible PDE5-Is and alprostadil from 1998 to 2024. Government expenditure was included and trends compared with international cohorts.
resultsAcross 260 756 procedures (17 882 PPI; 242 874 ICI), PPI sharply declined in 1996-1999 (CAGR -16.02%/year) after sildenafil introduction but demonstrated sustained growth over time (+7.08%/year 2000-2009 and +4.73%/year 2010-2020). Growth slowed to +1.94%/year 2020-2024 with COVID-related elective surgery disruptions. ICI use collapsed after 1998, stabilised in the 2010s, and contracted further during COVID, equating to a 97% reduction (CAGR -11.4%/year). PPI shifted toward older men aged 55-84 with marked increase in those aged 65-74 and 75-84 years, while ICI has transitioned to almost exclusive use in men over 55 years old. Government expenditure declined more than sixfold between 1996 and 2003 but plateaued since 2010 with PPI and ICI maintaining similar annual cost. From 1999 to 2024, RPBS-subsidised PDE5-Is prescriptions rose from ~440 to 25 500 yearly prescriptions, with early sildenafil predominance shifting to tadalafil, which accounts for 58% of use in 2024.
conclusionThere has been a considerable change in trends of invasive ED therapies over the past 30 years since the introduction of PDE5-Is. There has been a significant decline in ICI therapy over the study period, with a recent increased uptake in PPI utilisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.